|
1
|
Sammartino P, Sibio S, Biacchi D, Cardi M,
Mingazzini P, Rosati MS, Cornali T, Sollazzo B, Atta JM and Di
Giorgio A: Long-term results after proactive management for
locoregional control in patients with colonic cancer at high risk
of peritoneal metastases. Int J Colorectal Dis. 29:1081–1089.
2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Sugarbaker PH: New standard of care for
appendiceal epithelial neoplasms and pseudomyxoma peritonei
syndrome? Lancet Oncol. 7:69–76. 2006.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Sugarbaker PH, Turaga KK, Alexander HR Jr,
Deraco M and Hesdorffer M: Management of malignant peritoneal
mesothelioma using cytoreductive surgery and perioperative
chemotherapy. J Oncol Pract. 12:928–935. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Sugarbaker PH and Kwong ML: Regional
chemotherapy: Possibilities for prevention and treatment of
peritoneal metastases from gastric cancer. In: Management of
Gastric cancer. SMGroup. https://smjournals.com/ebooks/management-of-gastric-cancer/chapters/MGC-16-05.pdf.
Access date?
|
|
5
|
Sugarbaker PH: Prevention and treatment of
peritoneal metastases: A comprehensive review. Indian J Surg Oncol.
10:3–23. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Pestieau SR and Sugarbaker PH: Treatment
of primary colon cancer with peritoneal carcinomatosis: Comparison
of concomitant vs delayed management. Dis Colon Rectum.
43:1341–1348. 2000.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Tentes AA, Spiliotis ID, Korakianitis OS,
Vaxevanidou A and Kyziridis D: Adjuvant perioperative
intraperitoneal chemotherapy in locally advanced colorectal
carcinoma: Preliminary results. ISRN Surg.
2011(529876)2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Noura S, Ohue M, Shingai T, Kano S,
Ohigashi H, Yano M, Ishikawa O, Takenaka A, Murata K and Kameyama
M: Effects of intraperitoneal chemotherapy with mitomycin C on the
prevention of peritoneal recurrence in colorectal cancer patients
with positive peritoneal lavage cytology findings. Ann Surg Oncol.
18:396–404. 2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Glehen O, Kwiatkowski F, Sugarbaker PH,
Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F,
Quenet F, et al: Cytoreductive surgery combined with perioperative
intraperitoneal chemotherapy for the management of peritoneal
carcinomatosis from colorectal cancer: A multi-institutional study.
J Clin Oncol. 22:3284–3292. 2004.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sugarbaker PH, van der Speeten K, Stuart
OA, Chang D and Mahteme H: Patient- and treatment-related
variables, adverse events and their statistical relationship for
treatment of peritoneal metastases. In: Cytoreductive Surgery and
Perioperative Chemotherapy for Peritoneal Surface Malignancy.
Textbook and Video Atlas. Sugarbaker PH (ed). Cine-Med Publishing,
Woodbury, NY, pp183-206, 2012.
|
|
11
|
Verwaal VJ, van Ruth S, de Bree E, van
Sloothen GW, van Tinteren H, Boot H and Zoetmulder FA: Randomized
trial of cytoreduction and hyperthermic intraperitoneal
chemotherapy versus systemic chemotherapy and palliative surgery in
patients with peritoneal carcinomatosis of colorectal cancer. J
Clin Oncol. 21:3737–3743. 2003.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Verwaal VJ, Bruin S, Boot H, van Slooten G
and van Tinteren H: 8-year follow-up of randomized trial:
Cytoreduction and hyperthermic intraperitoneal chemotherapy versus
systemic chemotherapy in patients with peritoneal carcinomatosis of
colorectal cancer. Ann Surg Oncol. 15:2426–2432. 2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Elias D, Benizri E, Pocard M, Ducreux M,
Boige V and Lasser P: Treatment of synchronous peritoneal
carcinomatosis and liver metastases from colorectal cancer. Eur J
Surg Oncol. 32:632–636. 2006.PubMed/NCBI View Article : Google Scholar
|
|
14
|
de Cuba EM, Kwakman R, Knol DL, Bonjer HJ,
Meijer GA and Te Velde EA: Cytoreductive surgery and HIPEC for
peritoneal metastases combined with curative treatment of
colorectal liver metastases: Systematic review of all literature
and meta-analysis of observational studies. Cancer Treat Rev.
39:321–327. 2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Tan GH, Teo MC, Chen W, Lee SY, Ng DW,
Tham CK and Soo KC: Surgical management of colorectal peritoneal
metastases: Treatment and outcomes compared with hepatic
metastases. J Gastrointest Cancer. 44:170–176. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Abreu de Carvalho LF, Scuderi V, Maes H,
Cupo P, Geerts B, Van Bockstal M, Gremonprez F, Willaert W, Pattyn
P, Troisi R, et al: Simultaneous parenchyma-preserving liver
resection, cytoreductive surgery and intraperitoneal chemotherapy
for stage IV colorectal cancer. Acta Chir Belg. 115:261–267.
2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Alzahrani N, Ung L, Valle SJ, Liauw W and
Morris DL: Synchronous liver resection with cytoreductive surgery
for the treatment of liver and peritoneal metastases from colon
cancer: Results from an Australian centre. ANZ J Surg.
87:E167–E172. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Baratti D, Kusamura S, Iusco D, Cotsoglou
C, Guaglio M, Battaglia L, Virzi S, Mazzaferro V and Deraco M:
Should a history of extraperitoneal disease be a contraindication
to cytoreductive surgery and hyperthermic intraperitoneal
chemotherapy for colorectal cancer peritoneal metastases? Dis Colon
Rectum. 61:1026–1034. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Lorimier G, Linot B, Paillocher N,
Dupoiron D, Verriele V, Wernert R, Hamy A and Capitain O: Curative
cytoreductive surgery followed by hyperthermic intraperitoneal
chemotherapy in patients with peritoneal carcinomatosis and
synchronous resectable liver metastases arising from colorectal
cancer. Eur J Surg Oncol. 43:150–158. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Navez J, Remue C, Leonard D, Bachmann R,
Kartheuser A, Hubert C, Coubeau L, Komuta M, Van den Eynde M, Zech
F and Jabbour N: Surgical treatment of colorectal cancer with
peritoneal and liver metastases using combined liver and
cytoreductive surgery and hyperthermic intraperitoneal
chemotherapy: Report from a single-centre experience. Ann Surg
Oncol. 23 (Suppl 5):S666–S673. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Delhorme JB, Dupont-Kazma L, Addeo P,
Lefebvre F, Triki E, Romain B, Meyer N, Bachellier P, Rohr S and
Brigand C: Peritoneal carcinomatosis with synchronous liver
metastases from colorectal cancer: Who will benefit from complete
cytoreductive surgery? Int J Surg. 25:98–105. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Jeon Y, Park EJ, Lim JH and Baik SH:
Clinical outcomes of complete cytoreduction with concurrent liver
resection followed by hyperthermic intraperitoneal chemotherapy for
synchronous peritoneal and liver metastatic colorectal cancer.
World J Surg Oncol. 17(214)2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Pinto A, Hobeika C, Philis A, Kirzin S,
Carrere N and Ghouti L: Synchronous liver metastases and peritoneal
carcinomatosis from colorectal cancer: Different strategies for
curative treatment? Langenbecks Arch Surg. 404:477–488.
2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Soldevila-Verdeguer C, Segura-Sampedro JJ,
Pineno-Flores C, Sanchis-Cortes P, Gonzalez-Argente X and
Morales-Soriano R: Hepatic resection and blood transfusion increase
morbidity after cytoreductive surgery and HIPEC for colorectal
carcinomatosis. Clin Transl Oncol. 22:2032–2039. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Quenet F, Elias D, Roca L, Goere D, Ghouti
L, Pocard M, Facy O, Arvieux C, Lorimier G, Pezet D, et al: A
UNICANCER phase III trial of hyperthermic intra-peritoneal
chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC):
PRODIGE 7. J Clin Oncol. 36 (Suppl 18)(LBA3503)2018.
|
|
26
|
Bakkers C, van Erning FN, Rovers KP,
Nienhuijs SW, Burger JW, Lemmens VE, Aalbers AG, Kok NF, Boerma D,
Brandt AR, et al: Long-term survival after hyperthermic
intraperitoneal chemotherapy using mitomycin C or oxaliplatin in
colorectal cancer patients with synchronous peritoneal metastases:
A nationwide comparative study. Eur J Surg Oncol. 46:1902–1907.
2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Al Shammaa HA, Li Y and Yonemura Y:
Current status and future strategies of cytoreductive surgery plus
intraperitoneal hyperthermic chemotherapy for peritoneal
carcinomatosis. World J Gastroenterol. 14:1159–1166.
2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Jayne DG, Fook S, Loi C and Seow-Choen F:
Peritoneal carcinomatosis from colorectal cancer. Br J Surg.
89:1545–1550. 2002.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Grundmann RT: Current state of surgical
treatment of liver metastases from colorectal cancer. World J
Gastrointest Surg. 3:183–196. 2011.PubMed/NCBI View Article : Google Scholar
|
|
30
|
da Silva RG and Sugarbaker PH: Analysis of
prognostic factors in seventy patients having a complete
cytoreduction plus perioperative intraperitoneal chemotherapy for
carcinomatosis from colorectal cancer. J Am Coll Surg. 203:878–886.
2006.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Goere D, Souadka A, Faron M, Cloutier AS,
Viana B, Honore C, Dumont F and Elias D: Extent of colorectal
peritoneal carcinomatosis: Attempt to define a threshold above
which HIPEC does not offer survival benefit: A comparative study.
Ann Surg Oncol. 22:2958–2964. 2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Sugarbaker PH: Pseudomyxoma peritonei and
peritoneal metastases from appendiceal malignancy. In:
Cytoreductive Surgery and Perioperative Chemotherapy for Peritoneal
Surface Malignancy. Textbook and Video Atlas. 2nd edition.
Sugarbaker PH (ed). Cine-Med Publishers, Woodbury, NY, pp109-132,
2017.
|
|
33
|
Hentzen JEKR, van der Plas WY, Kuipers H,
Ramcharan S, Been LB, Hoogwater FJH, van Ginkel RJ, van Dam GM,
Hemmer PHJ and Kruijff S: Delta peritoneal cancer index (ΔPCI): A
new dynamic prognostic parameter for survival in patients with
colorectal peritoneal metastases. Eur J Surg Oncol. 46:590–599.
2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Elias D, Mariani A, Cloutier AS, Blot F,
Goere D, Dumont F, Honore C, Billard V, Dartigues P and Ducreux M:
Modified selection criteria for complete cytoreductive surgery plus
HIPEC based on peritoneal cancer index and small bowel involvement
for peritoneal carcinomatosis of colorectal origin. Eur J Surg
Oncol. 40:1467–1473. 2014.PubMed/NCBI View Article : Google Scholar
|
|
35
|
BacalbaSa N, Balescu I, Dima S and Popescu
I: The role of re-resection for breast cancer liver metastases-a
single center experience. Anticancer Res. 35:6877–6880.
2015.PubMed/NCBI
|
|
36
|
BacalbaSa N, Balescu I, Dima S and Popescu
I: Long-term survivors after liver resection for ovarian cancer
liver metastases. Anticancer Res. 35:6919–6923. 2015.PubMed/NCBI
|
|
37
|
BacalbaSa N, Balescu I, Dima S and Popescu
I: Long-term survivors after liver resection for breast cancer
liver metastases. Anticancer Res. 35:6913–6917. 2015.PubMed/NCBI
|
|
38
|
BacalbaSa N, Dima SO, Purtan-Purnichescu
R, Herlea V and Popescu I: Role of surgical treatment in breast
cancer liver metastases: A single center experience. Anticancer
Res. 34:5563–5568. 2014.PubMed/NCBI
|
|
39
|
BacalbaSa N, Dima S, Brasoveanu V, David
L, Balescu I, Purnichescu-Purtan R and Popescu I: Liver resection
for ovarian cancer liver metastases as part of cytoreductive
surgery is safe and may bring survival benefit. World J Surg Oncol.
13(235)2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Bacalbasa N, Brezean I, Anghel C, Barbu I,
Pautov M, Balescu I and Brasoveanu V: Successful resection and
vascular ligation of a large hepatic artery aneurysm-a case report
and literature review. In Vivo. 31:979–982. 2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
BacalbaSa N, Brezean I, Anghel C, Barbu I,
Pautov M, Balescu I and Brasoveanu V: Management of a fulminant
upper gastrointestinal bleeding exteriorized through hemobilia due
to arteriobiliary fistula between the common bile duct and a right
hepatic artery aneurysm-a case report. In Vivo. 31:983–989.
2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Hackl C, Neumann P, Gerken M, Loss M,
Klinkhammer-Schalke M and Schlitt HJ: Treatment of colorectal liver
metastases in Germany: A ten-year population-based analysis of 5772
cases of primary colorectal adenocarcinoma. BMC Cancer.
14(810)2014.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Adam R, Wicherts DA, de Haas RJ, Ciacio O,
Levi F, Paule B, Ducreux M, Azoulay D, Bismuth H and Castaing D:
Patients with initially unresectable colorectal liver metastases:
Is there a possibility of cure? J Clin Oncol. 27:1829–1835.
2009.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Khrizman P and Mulcahy MF: Curative
approach for stage IV colorectal cancer with multiorgan
involvement: What makes sense and what doesn't? Curr Colorectal
Cancer Rep. 6:97–107. 2010.
|
|
45
|
Esquivel J, Sticca R, Sugarbaker P, Levine
E, Yan TD, Alexander R, Baratti D, Bartlett D, Barone R, Barrios P,
et al: Cytoreductive surgery and hyperthermic intraperitoneal
chemotherapy in the management of peritoneal surface malignancies
of colonic origin: A consensus statement. Society of surgical
oncology. Ann Surg Oncol. 14:128–133. 2007.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Bushati M, Rovers KP, Sommariva A,
Sugarbaker PH, Morris DL, Yonemura Y, Quadros CA, Somashekhar SP,
Ceelen W, Dube P, et al: The current practice of cytoreductive
surgery and HIPEC for colorectal peritoneal metastases: Results of
a worldwide web-based survey of the peritoneal surface oncology
group international (PSOGI). Eur J Surg Oncol. 44:1942–1948.
2018.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Steffen T, Eden J, Bijelic L, Glatzer M,
Glehen O, Goéré D, de Hingh I, Li Y, Moran B, Morris D, et al:
Patient selection for hyperthermic intraperitoneal chemotherapy in
patients with colorectal cancer: Consensus on decision making among
international experts. Clin Colorectal Cancer. 19:277–284.
2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Vassos N and Piso P: Metastatic colorectal
cancer to the peritoneum: Current treatment options. Curr Treat
Options Oncol. 19(49)2018.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Maggiori L, Goere D, Viana B, Tzanis D,
Dumont F, Honore C, Eveno C and Elias D: Should patients with
peritoneal carcinomatosis of colorectal origin with synchronous
liver metastases be treated with a curative intent? A case-control
study. Ann Surg. 258:116–121. 2013.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Downs-Canner S, Shuai Y, Ramalingam L,
Pingpank JF, Holtzman MP, Zeh HJ, Bartlett DL and Choudry HA:
Safety and efficacy of combined resection of colorectal peritoneal
and liver metastases. J Surg Res. 219:194–201. 2017.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Graf W, Cashin PH, Ghanipour L, Enblad M,
Botling J, Terman A and Birgisson H: Prognostic impact of BRAF and
KRAS mutation in patients with colorectal and appendiceal
peritoneal metastases scheduled for CRS and HIPEC. Ann Surg Oncol.
27:293–300. 2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Morgan Z, Chow BE, Strong EA, Tsai S,
Christians K, Mogal H, Gamblin TC and Clarke CN: RAS mutation
status confers prognostic relevance in patients treated with
cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
for colorectal cancer. J Surg Res. 240:130–135. 2019.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Cascales-Campos PA, Lopez-Lopez V,
Torres-Melero J, Arjona A, Munoz-Casares FC, Barrios P, Morales R,
Pereira F, Bretcha-Boix P, Gonzalez-Bayon L, et al: Survival
outcomes in patients aged 75 years and over with peritoneal
colorectal carcinomatosis after cytoreductive surgery and
hyperthermic intraperitoneal chemotherapy (HIPEC): Multicenter
study of the Spanish group of peritoneal cancer surgery (GECOP).
Clin Transl Oncol. 22:130–136. 2020.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Cloyd JM, Abdel-Misih S, Hays J, Dillhoff
ME, Pawlik TM and Schmidt C: Impact of synchronous liver resection
on the perioperative outcomes of patients undergoing CRS-HIPEC. J
Gastrointest Surg. 22:1576–1584. 2018.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Clavien PA, Barkun J, de Oliveira ML,
Vauthey JN, Dindo D, Schulick RD, de Santibanes E, Pekolj J,
Slankamenac K, Bassi C, et al: The Clavien-Dindo classification of
surgical complications: Five-year experience. Ann Surg.
250:187–196. 2009.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Baratti D, Kusamura S, Azmi N, Guaglio M,
Montenovo M and Deraco M: Colorectal peritoneal metastases treated
by perioperative systemic chemotherapy and cytoreductive surgery
with or without mitomycin C-Based HIPEC: A comparative study using
the peritoneal surface disease severity score (PSDSS). Ann Surg
Oncol. 27:98–106. 2020.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Ferron G, Dattez S, Gladieff L, Delord JP,
Pierre S, Lafont T, Lochon I and Chatelut E: Pharmacokinetics of
heated intraperitoneal oxaliplatin. Cancer Chemother Pharmacol.
62:679–683. 2008.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Mahteme H, Wallin I, Glimelius B, Pahlman
L and Ehrsson H: Systemic exposure of the parent drug oxaliplatin
during hyperthermic intraperitoneal perfusion. Eur J Clin
Pharmacol. 64:907–911. 2008.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Elias D, Lefevre JH, Chevalier J, Brouquet
A, Marchal F, Classe JM, Ferron G, Guilloit JM, Meeus P, Goere D
and Bonastre J: Complete cytoreductive surgery plus intraperitoneal
chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of
colorectal origin. J Clin Oncol. 27:681–685. 2009.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Quenet F, Goere D, Mehta SS, Roca L,
Dumont F, Hessissen M, Saint-Aubert B and Elias D: Results of two
bi-institutional prospective studies using intraperitoneal
oxaliplatin with or without irinotecan during HIPEC after
cytoreductive surgery for colorectal carcinomatosis. Ann Surg.
254:294–301. 2011.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Wisselink DD, Braakhuis LLF, Gallo G, van
Grevenstein WMU, van Dieren S, Kok NFM, de Reuver PR, Tanis PJ and
de Hingh IHJT: Systematic review of published literature on
oxaliplatin and mitomycin C as chemotherapeutic agents for
hyperthermic intraperitoneal chemotherapy in patients with
peritoneal metastases from colorectal cancer. Crit Rev Oncol
Hematol. 142:119–129. 2019.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Hulshof EC, Lurvink RJ, Caserta N, de
Hingh IHJT, van Wezel T, Bohringer S, Swen JJ, Gelderblom H,
Guchelaar HJ and Deenen MJ: Identification of pharmacogenetic
biomarkers for efficacy of cytoreductive surgery plus hyperthermic
intraperitoneal mitomycin C in patients with colorectal peritoneal
metastases. Eur J Surg Oncol. 46:1925–1931. 2020.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Glockzin G, Gerken M, Lang SA,
Klinkhammer-Schalke M, Piso P and Schlitt HJ: Oxaliplatin-based
versus irinotecan-based hyperthermic intraperitoneal chemotherapy
(HIPEC) in patients with peritoneal metastasis from appendiceal and
colorectal cancer: A retrospective analysis. BMC Cancer.
14(807)2014.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Hompes D, Aalbers A, Boot H, van
Velthuysen ML, Vogel W, Prevoo W, van Tinteren H and Verwaal V: A
prospective pilot study to assess neoadjuvant chemotherapy for
unresectable peritoneal carcinomatosis from colorectal cancer.
Colorectal Dis. 16:O264–O272. 2014.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Klaver YL, de Hingh IH, Boot H and Verwaal
VJ: Results of cytoreductive surgery and hyperthermic
intraperitoneal chemotherapy after early failure of adjuvant
systemic chemotherapy. J Surg Oncol. 103:431–434. 2011.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Waite K and Youssef H: The role of
neoadjuvant and adjuvant systemic chemotherapy with cytoreductive
surgery and heated intraperitoneal chemotherapy for colorectal
peritoneal metastases: A systematic review. Ann Surg Oncol.
24:705–720. 2017.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Kabbinavar FF, Hambleton J, Mass RD,
Hurwitz HI, Bergsland E and Sarkar S: Combined analysis of
efficacy: The addition of bevacizumab to fluorouracil/leucovorin
improves survival for patients with metastatic colorectal cancer. J
Clin Oncol. 23:3706–3712. 2005.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Saltz LB, Clarke S, Diaz-Rubio E,
Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS,
Rivera F, et al: Bevacizumab in combination with oxaliplatin-based
chemotherapy as first-line therapy in metastatic colorectal cancer:
A randomized phase III study. J Clin Oncol. 26:2013–2019.
2008.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Hapani S, Chu D and Wu S: Risk of
gastrointestinal perforation in patients with cancer treated with
bevacizumab: A meta-analysis. Lancet Oncol. 10:559–568.
2009.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Eveno C, Passot G, Goere D, Soyer P, Gayat
E, Glehen O, Elias D and Pocard M: Bevacizumab doubles the early
postoperative complication rate after cytoreductive surgery with
hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal
carcinomatosis of colorectal origin. Ann Surg Oncol. 21:1792–1800.
2014.PubMed/NCBI View Article : Google Scholar
|
